Cabo VerdeTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.027 (0.026–0.029) 5.3 (4.9–5.6)
Mortality (HIV+TB only) 0.037 (0.024–0.051) 7 (4.7–9.9)
Incidence  (includes HIV+TB) 0.72 (0.47–1) 139 (90–198)
Incidence (HIV+TB only) 0.084 (0.053–0.12) 16 (10–23)
Incidence (MDR/RR-TB)** 0.027 (0–0.055) 5.2 (0–11)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0 (0–0.032) 0.16 (<0.01–0.31) 0.16 (0–0.35)
Males 0.084 (0.05–0.12) 0.48 (0.33–0.63) 0.56 (0.38–0.75)
Total 0.084 (0.054–0.11) 0.64 (0.48–0.8) 0.72 (0.47–1)
TB case notifications, 2015  
Total cases notified 272
Total new and relapse 269
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 37% (26–57)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.06–0.14)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 31 12%
          - on antiretroviral therapy 24 77%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  11
(1–21)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 92% 276
Previously treated cases, excluding relapse, registered in 2014 58% 19
HIV-positive TB cases, all types, registered in 2014 85% 27
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 76%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) <1
Funding source: 94% domestic, 6% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data